Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Brainstorm Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of autologous adult stem cell therapies for neurodegenerative diseases. The company operates within the biopharmaceutical and regenerative medicine industries, with its core research centered on cell-based treatments designed to modulate neuroinflammation and support neuronal survival.
Its primary product candidate is NurOwn®, an investigational autologous mesenchymal stem cell therapy evaluated primarily for amyotrophic lateral sclerosis (ALS) and previously for other neurological conditions. The company does not have any FDA-approved products and has not generated product revenue, relying instead on grants, equity financing, and research collaborations. Brainstorm’s strategic positioning is based on its proprietary cell-processing platform and expertise in personalized cell therapy manufacturing. The company was founded in 2000; while public disclosures consistently confirm the year of incorporation, founder attribution is not consistently detailed across public sources, and specific founder information is therefore data inconclusive based on available public sources.
Business Operations
Brainstorm operates as a single-segment, research-and-development-focused biotechnology company. Its business activities are concentrated on the development, clinical testing, and regulatory advancement of NurOwn®, which is manufactured using a proprietary process that differentiates mesenchymal stem cells into neurotrophic factor–secreting cells. The company’s operations include clinical trial management, regulatory engagement, and small-scale manufacturing for clinical use.
Operationally, Brainstorm conducts R&D activities in both the United States and Israel, supported by its wholly owned subsidiary BrainStorm Cell Therapeutics Ltd. The company has historically collaborated with academic medical centers and hospitals for clinical trials but does not currently report any material commercial joint ventures. As of the most recent public disclosures, Brainstorm has significantly reduced operational expenditures and workforce following regulatory setbacks, with activities focused on data analysis, strategic review, and preservation of intellectual property.
Strategic Position & Investments
Brainstorm’s strategic direction has centered on demonstrating the clinical and regulatory viability of NurOwn® in ALS, a disease with limited therapeutic options. Following an unfavorable advisory committee outcome and regulatory feedback from the U.S. Food and Drug Administration regarding its ALS program, the company announced a strategic reassessment, including cost reductions and evaluation of strategic alternatives.
The company’s investment focus has historically been internal, directed toward clinical trials, manufacturing capabilities, and intellectual property related to its cell therapy platform. Brainstorm has not completed any major acquisitions and does not maintain a diversified portfolio of subsidiaries beyond BrainStorm Cell Therapeutics Ltd. Its emerging technology exposure remains concentrated in autologous stem cell processing and neurotrophic factor delivery, with future development pathways dependent on strategic partnerships, additional capital, or licensing arrangements.
Geographic Footprint
Brainstorm is headquartered in New York, United States, with significant operational and research activities conducted in Israel through its subsidiary BrainStorm Cell Therapeutics Ltd. Clinical development efforts have primarily involved sites in North America and Israel, reflecting the company’s focus on U.S. and Israeli regulatory pathways.
The company does not maintain a commercial presence across multiple continents, as it has no approved products. However, its intellectual property portfolio and clinical collaborations give it an international footprint within the global biotechnology research ecosystem, particularly in regions with established expertise in stem cell research and neurodegenerative disease treatment.
Leadership & Governance
Brainstorm is led by executives with backgrounds in biotechnology, finance, and clinical neurology, with governance overseen by a board of directors responsible for strategic oversight and regulatory compliance. Management has emphasized scientific rigor, regulatory engagement, and capital discipline, particularly following recent clinical and regulatory challenges.
Key executives include:
- Chaim Lebovits – President and Chief Executive Officer
- Michael Wood – Chief Financial Officer
- Dimitrios Karussis, MD, PhD – Chief Medical Officer
The leadership team’s stated strategic vision has focused on advancing cell-based therapies for neurodegenerative diseases while maintaining flexibility to pursue partnerships or alternative strategic paths in response to regulatory outcomes and capital market conditions.